NeurAxis Bets on Payer Confidence and a VA Launch to Turn Coverage into Scale

Q2 revenue jumped 116% as management accelerates into covered markets, but a 30% drawdown suggests the market remains skeptical until the two large payers actually write policy.

NRXS · Earnings Call · 2026-08-11

Coverage: The Confidence Is Real, the Names Are Not

Q2 was a milestone quarter for NeurAxis, but the stock's 30% drawdown since May signals that investors are still waiting for the one thing management can't control: new insurance policy. Yet CEO Brian Carrico's confidence is palpably higher. On the call he said, “we're basically treating no one” — Brian Carrico, CEO · 2026-08-11 — a striking admission that despite 116% revenue growth, the addressable patient pool remains nearly untapped. The reason is coverage: hospitals need a critical mass before they fully activate. In response to a direct question, Carrico confirmed the threshold is “70%” — Brian Carrico, CEO · 2026-08-11 of a hospital's payer mix. That echoes his prior guidance from the May call, where he said it needed to be “at least 50%, closer to 60 or 70%” — Brian Carrico, Chief Executive Officer · 2026-05-12. What changed is the caliber of payer engagement. Carrico revealed direct conversations with two large payers, stating, “we've had direct conversations with a payer who made comments or alluded to the fact that they believe this should also be a covered service.” — Brian Carrico, CEO · 2026-08-11 He also announced the creation of a VP of Healthcare Economics and Policy to institutionalize the market access push. This is a clear escalation from the prior quarters' general optimism.

The Commercial Pivot: Saturate, Don't Scatter

Management has learned from Q1 that the Category 1 CPT code works only where coverage is strong. The new strategy is to concentrate resources in six to eight states with favorable commercial infrastructure, backed by a slew of new hires: a VP of Sales, a VP of Marketing, a medical science liaison, and a clinical adoption director. The message is consistent:

our sole commercial focus is to execute aggressively in markets where policy coverage exists and prepare the commercial infrastructure to scale as additional coverage comes online.
Brian Carrico, CEO · 2026-08-11

This is a deliberate shift from the earlier "measure twice, cut once" posture. On the prior call, Carrico noted, “We have been very lean, and that is because we needed a revenue source in the Category I CPT code and an FSS contract.” — Brian Carrico, Chief Executive Officer (CEO) · 2026-03-19 Now that those are in hand, he's willing to spend, even if it pushes out profitability. "I'm here to drive revenue," he said in response to an analyst question about OpEx — a stark contrast to his earlier caution.

The VA: A Second Growth Platform

The most concrete new development is the VA expansion. The company has already secured a federal supply schedule contract and is now launching with 10 1099 territory reps, each covering one to three VA hospitals. The VA hospitals channel offers a path that bypasses commercial payer coverage, and early reorders validate the demand. Management expects the reps to be trained and selling by September 15, with a clear read on the opportunity by year-end. This is a genuine strategic pivot, opening an adult indication that could ultimately feed into the large adult RCT at Cleveland Clinic.

The Numbers Tell a Story of Leverage—and Risk

Revenue for Q2 came in at $1.928M, up 116% YoY, while gross margin expanded to 85.9%. The fundamentals confirm the trajectory: Total Revenue reached $2.0M in the latest period, up 80% YoY per the 10-Q (though the call cites 116% for the calendar quarter). Yet the company still lost $2.1M in the quarter, and the cash burn, while down to $1.1M per quarter, is expected to rise in H2 as the hiring and VA launch take effect. The burn rate remains the key watchpoint, and management's own CFO admitted the going concern language will remain until coverage actually converts into profits. The stock's 30% drawdown from its May peak suggests investors are pricing in execution risk. NeurAxis has made the bold bet that payer momentum, combined with a disciplined commercial push, will finally fill the bucket. The next two quarters will reveal whether the confidence is justified.